Households with users of GLP-1 agonists have already reduced their grocery spending by 5.3% to 8%, a seismic shift in consumer behavior that snack brands are only beginning to confront. A significant reduction in purchasing power represents a direct challenge to the traditional growth models of the packaged food industry, where every percentage point of reduced spending translates into millions in lost revenue. Approximately 5% to 12.5% of US adults are currently taking GLP-1 agonists, a substantial and growing segment of the population whose dietary habits are being fundamentally altered.
However, while GLP-1 drug usage is rapidly expanding and directly reducing consumer grocery spending, snack unit sales have remained stable, creating a false sense of security for the industry. An apparent contradiction masks a deeper erosion of profitability and a potential future decline in volume, as the underlying drivers of consumer demand shift.
Ultimately, packaged food companies are likely to face increasing pressure on sales and profit margins, necessitating a rapid and fundamental re-evaluation of product portfolios and business models to cater to a less hungry consumer base. The long-term implications for the snack industry, particularly regarding health trends, weight loss drugs, and their impact on snack brands in 2026, demand a strategic overhaul rather than incremental adjustments.
Approximately 5% to 12.5% of US adults are currently taking GLP-1 agonists, a public health intervention now profoundly influencing consumer markets. The segment of the population, which includes users of medications like Wegovy and Zepbound, has demonstrably altered its purchasing habits. Households with GLP-1 users have reduced their overall grocery spending by 5.3% to 8%, a critical metric for an industry historically reliant on consistent consumer volume.
The Wall Street Journal warns that GLP-1 drugs pose a threat to billions in sales for packaged-food makers. The threat extends beyond mere calorie reduction; it signifies a fundamental re-evaluation of how consumers approach food consumption, particularly discretionary items like snacks. The significant reduction in household grocery spending directly translates into a massive potential revenue loss for the packaged food sector, an urgent need for strategic adaptation. Companies can no longer assume consistent per-capita consumption of their products.
Given that Wegovy® or Zepbound® can cost as little as $25 per fill with insurance and savings cards, according to JumpstartMD, the rapid and widespread adoption of GLP-1s is inevitable. The affordability factor accelerates the market penetration of these drugs, meaning the snack industry's 'billions in sales' threat, as reported by The Wall Street Journal, is not a distant future but an accelerating present reality. The economic feasibility for a broad demographic ensures that the impact on consumer demand will only intensify.
The Immediate Financial Shockwave
Shares of Greggs, the UK bakery and fast-food chain, fell as much as 6% on a Monday following warnings about the impact of weight-loss drugs. Investment bank Jefferies warned that these medications could significantly curb sales and profit growth for Greggs, a company heavily reliant on impulse snack purchases, according to Reuters. The immediate market reaction underscores the financial community's growing recognition of the profound changes obesity drugs are enacting on consumer demand, particularly in the United States, as noted by Reuters.
The swift decline in Greggs' valuation, even as companies are still largely "exploring strategies" to adapt, demonstrates that investor confidence in the packaged food sector is already being directly eroded by the drug's influence. It is not a speculative future concern but an active re-evaluation of company prospects based on projected shifts in consumer behavior. The immediate market reaction to GLP-1 drug projections, exemplified by Greggs' stock drop, proves that investors are already pricing in the significant threat these drugs pose to traditional food company revenues. Companies that delay acknowledging this fundamental shift risk a measurable and immediate devaluation.
The 6% fall in Greggs' shares, as reported by Reuters, serves as a stark warning that investors are already pricing in the negative impact of GLP-1s. suggesting that companies slow to acknowledge and fundamentally adapt to reduced consumer appetite face measurable and immediate market value erosion. The expectation is that similar pressures will materialize across the broader snack industry as the prevalence of GLP-1 users continues to expand.
Are Weight Loss Drugs Affecting the Snack Industry in 2026?
Despite clear indicators of reduced consumer spending, USDA data reveals that snack unit sales remained stable at over 10 billion per year in 2024, mirroring levels observed in 2020, according to FoodNavigator. The apparent stability creates a deceptive calm amidst a period of significant consumer behavioral shifts driven by GLP-1 agonists. While the overall grocery spending by households with GLP-1 users has decreased by 5.3% to 8%, the consistent snack unit volume suggests a complex interplay of market forces that may be masking deeper issues for snack brands.
The tension between stable unit sales and reduced overall grocery spending implies that while the sheer number of snack units sold remains consistent, the value or profitability per unit is likely declining. This could be due to increased promotional activities, a shift towards lower-priced snack options, or a change in the demographics of snack purchasers. The stable units could also be masking a significant shift in what types of snacks are being purchased, with consumers potentially opting for "healthier" or lower-calorie alternatives, or a redistribution of purchases among different consumer groups.
Ultimately, while current snack sales appear stable, this masks the underlying shift in consumer behavior driven by GLP-1s, suggesting that the full impact on sales volume is yet to materialize or is being offset by other factors. This creates a false sense of security for the industry, as the foundational economics of snack consumption are eroding even if top-line unit numbers remain steady. The industry cannot afford to misinterpret this stability as resilience when deeper market forces are at play.
Industry's Strategic Pivot
Global food and beverage companies are already responding to these evolving consumer preferences by focusing on shorter ingredient lists and smaller pack sizes in 2026, according to Reuters. The strategic pivot reflects an acknowledgment among major players that the era of maximizing volume through large, indulgent portions may be drawing to a close. Packaged-food companies are actively exploring strategies to engage consumers who are less hungry, a direct consequence of GLP-1 agonist usage, as reported by The Wall Street Journal.
The proactive shift by major food companies towards smaller portions and simpler ingredients indicates a clear recognition of the GLP-1 driven market transformation. It marks a move away from past volume-centric strategies that prioritized quantity over perceived health benefits. However, while these adjustments are a step toward acknowledging the new consumer reality, they represent tactical changes rather than a full strategic overhaul. The industry's current focus on minor adjustments like shorter ingredient lists and smaller pack sizes is a dangerous miscalculation.
Based on Reuters' report that global food and beverage companies are focusing on 'shorter ingredient lists and smaller pack sizes,' the packaged food industry is currently misdiagnosing the core problem posed by GLP-1s. It is implementing tactical changes when a strategic overhaul of product purpose and value proposition is needed. The fundamental reduction in appetite requires more than just repackaging existing products; it demands innovation in product development that aligns with reduced consumption and enhanced nutritional value.
The Future of Food: Accessibility and Affordability of GLP-1s
With commercial insurance that covers the drug and manufacturer savings cards, a fill of Wegovy® or Zepbound® can cost about $25 as of June 2026, according to JumpstartMD. The low out-of-pocket cost for many consumers ensures rapid and widespread adoption of GLP-1s, making these medications accessible to a broad demographic beyond high-income brackets. The affordability factor is a critical driver for the projected expansion of GLP-1 usage, solidifying the long-term challenge for the food industry.
Even without insurance coverage, the self-pay options for these medications are becoming more competitive. NovoCare® Pharmacy and LillyDirect® offer Wegovy and Zepbound for roughly $199 to $449 a month, depending on dose and offer, as of June 2026, as detailed by JumpstartMD. The introduction of oral options, such as the Wegovy® pill launched in early 2026 with a starter offer around $149 per month, further enhances accessibility and affordability. for the lowest dose, further enhances accessibility and convenience, removing the barrier of injectables for many potential users. LillyDirect® also sells single-dose Zepbound® vials for self-pay at $299/month (2.5 mg), $399/month (5 mg), and $449/month for all higher doses as of June 2026.
The increasing affordability and diverse availability of GLP-1 drugs, including oral options, will accelerate their adoption, making the shift in consumer eating habits a permanent and expanding challenge for the food industry. This sustained growth in user base means snack brands cannot view the current market changes as a temporary trend. Instead, they must prepare for a future where a significant portion of the consumer base consistently seeks smaller portions and different nutritional profiles, fundamentally altering the snack preferences in 2026 and beyond. By Q4 2026, major snack producers like Mondelēz International will likely be compelled to publicly revise growth projections, acknowledging the irreversible erosion of traditional demand driven by GLP-1s.
